 CAMBRIDGE, Mass., Sept. 27, 2021 GLOBE NEWSWIRE -- Intellia Therapeutics, Inc. NASDAQ:NTLA, a leading clinical-stage genome editing company focused on developing curative therapeutics using CRISPRCas9 technology both in vivo and ex vivo, will present at Chardans 5th Annual Genetic Medicines Conference on Monday, October 4, 2021 at 10:30 a.m. ET. 